Using a screening platform developed in-house, NexGenix has discovered and is developing a non-surgical intralesional treatment for dermal neurofibromas - the commonest lesion in NF1. The mode of action for NX101 is based on a vascular disruption mechanism. The Company has successfully performed 2 proof of concept pilot clinical trials for this approach, which represents a therapeutic switch of an existing drug.

NexGenix intends to pursue corporate partners in dermatology or drug delivery for this program, which likely will have applicability for the treatment of other skin conditions.